Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation
Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated...
Gespeichert in:
Veröffentlicht in: | Clinical genetics 2018-04, Vol.93 (4), p.905-912 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 912 |
---|---|
container_issue | 4 |
container_start_page | 905 |
container_title | Clinical genetics |
container_volume | 93 |
creator | Zaki, M.S. Issa, M.Y. Elbendary, H.M. El‐Karaksy, H. Hosny, H. Ghobrial, C. El Safty, A. El‐Hennawy, A. Oraby, A. Selim, L. Abdel‐Hamid, M.S. |
description | Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T > C (p.Leu26Pro), c.90C > G (p.Tyr30*), c.119A > C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G > C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder.
We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms ( |
doi_str_mv | 10.1111/cge.13184 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1971655271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2013610730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</originalsourceid><addsrcrecordid>eNp1kc1q3DAUhUVIaSbTLvICRZBNA3GiK_lP2YUhP4WBLtKuhca6zijYkivZTf0KfeqoM0kXhWpzEefTubr3EHIC7ALSuWwe8QIE1PkBWYCQMmOM5YdkkYrMJJTiiBzH-JSuoirke3LEJUjBRL4gv-_nAUOv3aN2GLG3mj7bcUvNHEfvrD6ng-_mZh63O007QxsbwtZHG6l1FBgd9GjRjfGKPthf1Pmf2NGH9Uqw6yT205hk7-LuaTuFZBTosEXnx9SZGuyswx3ygbxrdRfx42tdku-3N99W99n6692X1fU6a0Qh8szITc60lFXRSg15XeKmzVmdJgPkYHhRmbqs0oC50I3UvCo5Gm4EbJBBzbVYks973yH4HxPGUfU2Nth1aQN-igpkBWVR8AoSevoP-uSn4NLvFGcgSmBVWuOSnO2pJvgYA7ZqCLbXYVbA1J-AVApI7QJK7KdXx2nTo_lLviWSgMs98Gw7nP_vpFZ3N3vLF5XumbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013610730</pqid></control><display><type>article</type><title>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</title><source>Access via Wiley Online Library</source><creator>Zaki, M.S. ; Issa, M.Y. ; Elbendary, H.M. ; El‐Karaksy, H. ; Hosny, H. ; Ghobrial, C. ; El Safty, A. ; El‐Hennawy, A. ; Oraby, A. ; Selim, L. ; Abdel‐Hamid, M.S.</creator><creatorcontrib>Zaki, M.S. ; Issa, M.Y. ; Elbendary, H.M. ; El‐Karaksy, H. ; Hosny, H. ; Ghobrial, C. ; El Safty, A. ; El‐Hennawy, A. ; Oraby, A. ; Selim, L. ; Abdel‐Hamid, M.S.</creatorcontrib><description>Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T > C (p.Leu26Pro), c.90C > G (p.Tyr30*), c.119A > C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G > C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder.
We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (<2 years) with unexpected early hepatic involvement before the neurological regression in some patients. Treatment with 2,3 dimercaptosuccinic acid showed satisfactory results and improvement of biochemical markets, hepatic manifestations and relative amelioration of the neurological symptoms. Thus, we believe that we expanded the mutational spectrum and further delineate the phenotypic spectrum of this very rare inborn error of Mn metabolism.</description><identifier>ISSN: 0009-9163</identifier><identifier>EISSN: 1399-0004</identifier><identifier>DOI: 10.1111/cge.13184</identifier><identifier>PMID: 29193034</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Basal ganglia ; Biochemical markers ; Cirrhosis ; DMSA ; Dystonia ; early phenotype ; Genetic variability ; Liver cirrhosis ; Liver diseases ; Manganese ; Minority & ethnic groups ; Mutation ; Phenotypes ; Polycythemia ; SLC30A10</subject><ispartof>Clinical genetics, 2018-04, Vol.93 (4), p.905-912</ispartof><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</citedby><cites>FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</cites><orcidid>0000-0001-7840-0002</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcge.13184$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcge.13184$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29193034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaki, M.S.</creatorcontrib><creatorcontrib>Issa, M.Y.</creatorcontrib><creatorcontrib>Elbendary, H.M.</creatorcontrib><creatorcontrib>El‐Karaksy, H.</creatorcontrib><creatorcontrib>Hosny, H.</creatorcontrib><creatorcontrib>Ghobrial, C.</creatorcontrib><creatorcontrib>El Safty, A.</creatorcontrib><creatorcontrib>El‐Hennawy, A.</creatorcontrib><creatorcontrib>Oraby, A.</creatorcontrib><creatorcontrib>Selim, L.</creatorcontrib><creatorcontrib>Abdel‐Hamid, M.S.</creatorcontrib><title>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</title><title>Clinical genetics</title><addtitle>Clin Genet</addtitle><description>Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T > C (p.Leu26Pro), c.90C > G (p.Tyr30*), c.119A > C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G > C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder.
We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (<2 years) with unexpected early hepatic involvement before the neurological regression in some patients. Treatment with 2,3 dimercaptosuccinic acid showed satisfactory results and improvement of biochemical markets, hepatic manifestations and relative amelioration of the neurological symptoms. Thus, we believe that we expanded the mutational spectrum and further delineate the phenotypic spectrum of this very rare inborn error of Mn metabolism.</description><subject>Basal ganglia</subject><subject>Biochemical markers</subject><subject>Cirrhosis</subject><subject>DMSA</subject><subject>Dystonia</subject><subject>early phenotype</subject><subject>Genetic variability</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Manganese</subject><subject>Minority & ethnic groups</subject><subject>Mutation</subject><subject>Phenotypes</subject><subject>Polycythemia</subject><subject>SLC30A10</subject><issn>0009-9163</issn><issn>1399-0004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kc1q3DAUhUVIaSbTLvICRZBNA3GiK_lP2YUhP4WBLtKuhca6zijYkivZTf0KfeqoM0kXhWpzEefTubr3EHIC7ALSuWwe8QIE1PkBWYCQMmOM5YdkkYrMJJTiiBzH-JSuoirke3LEJUjBRL4gv-_nAUOv3aN2GLG3mj7bcUvNHEfvrD6ng-_mZh63O007QxsbwtZHG6l1FBgd9GjRjfGKPthf1Pmf2NGH9Uqw6yT205hk7-LuaTuFZBTosEXnx9SZGuyswx3ygbxrdRfx42tdku-3N99W99n6692X1fU6a0Qh8szITc60lFXRSg15XeKmzVmdJgPkYHhRmbqs0oC50I3UvCo5Gm4EbJBBzbVYks973yH4HxPGUfU2Nth1aQN-igpkBWVR8AoSevoP-uSn4NLvFGcgSmBVWuOSnO2pJvgYA7ZqCLbXYVbA1J-AVApI7QJK7KdXx2nTo_lLviWSgMs98Gw7nP_vpFZ3N3vLF5XumbA</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Zaki, M.S.</creator><creator>Issa, M.Y.</creator><creator>Elbendary, H.M.</creator><creator>El‐Karaksy, H.</creator><creator>Hosny, H.</creator><creator>Ghobrial, C.</creator><creator>El Safty, A.</creator><creator>El‐Hennawy, A.</creator><creator>Oraby, A.</creator><creator>Selim, L.</creator><creator>Abdel‐Hamid, M.S.</creator><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7840-0002</orcidid></search><sort><creationdate>201804</creationdate><title>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</title><author>Zaki, M.S. ; Issa, M.Y. ; Elbendary, H.M. ; El‐Karaksy, H. ; Hosny, H. ; Ghobrial, C. ; El Safty, A. ; El‐Hennawy, A. ; Oraby, A. ; Selim, L. ; Abdel‐Hamid, M.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Basal ganglia</topic><topic>Biochemical markers</topic><topic>Cirrhosis</topic><topic>DMSA</topic><topic>Dystonia</topic><topic>early phenotype</topic><topic>Genetic variability</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Manganese</topic><topic>Minority & ethnic groups</topic><topic>Mutation</topic><topic>Phenotypes</topic><topic>Polycythemia</topic><topic>SLC30A10</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaki, M.S.</creatorcontrib><creatorcontrib>Issa, M.Y.</creatorcontrib><creatorcontrib>Elbendary, H.M.</creatorcontrib><creatorcontrib>El‐Karaksy, H.</creatorcontrib><creatorcontrib>Hosny, H.</creatorcontrib><creatorcontrib>Ghobrial, C.</creatorcontrib><creatorcontrib>El Safty, A.</creatorcontrib><creatorcontrib>El‐Hennawy, A.</creatorcontrib><creatorcontrib>Oraby, A.</creatorcontrib><creatorcontrib>Selim, L.</creatorcontrib><creatorcontrib>Abdel‐Hamid, M.S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaki, M.S.</au><au>Issa, M.Y.</au><au>Elbendary, H.M.</au><au>El‐Karaksy, H.</au><au>Hosny, H.</au><au>Ghobrial, C.</au><au>El Safty, A.</au><au>El‐Hennawy, A.</au><au>Oraby, A.</au><au>Selim, L.</au><au>Abdel‐Hamid, M.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</atitle><jtitle>Clinical genetics</jtitle><addtitle>Clin Genet</addtitle><date>2018-04</date><risdate>2018</risdate><volume>93</volume><issue>4</issue><spage>905</spage><epage>912</epage><pages>905-912</pages><issn>0009-9163</issn><eissn>1399-0004</eissn><abstract>Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T > C (p.Leu26Pro), c.90C > G (p.Tyr30*), c.119A > C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G > C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder.
We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (<2 years) with unexpected early hepatic involvement before the neurological regression in some patients. Treatment with 2,3 dimercaptosuccinic acid showed satisfactory results and improvement of biochemical markets, hepatic manifestations and relative amelioration of the neurological symptoms. Thus, we believe that we expanded the mutational spectrum and further delineate the phenotypic spectrum of this very rare inborn error of Mn metabolism.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>29193034</pmid><doi>10.1111/cge.13184</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7840-0002</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-9163 |
ispartof | Clinical genetics, 2018-04, Vol.93 (4), p.905-912 |
issn | 0009-9163 1399-0004 |
language | eng |
recordid | cdi_proquest_miscellaneous_1971655271 |
source | Access via Wiley Online Library |
subjects | Basal ganglia Biochemical markers Cirrhosis DMSA Dystonia early phenotype Genetic variability Liver cirrhosis Liver diseases Manganese Minority & ethnic groups Mutation Phenotypes Polycythemia SLC30A10 |
title | Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A16%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypermanganesemia%20with%20dystonia,%20polycythemia%20and%20cirrhosis%20in%2010%20patients:%20Six%20novel%20SLC30A10%20mutations%20and%20further%20phenotype%20delineation&rft.jtitle=Clinical%20genetics&rft.au=Zaki,%20M.S.&rft.date=2018-04&rft.volume=93&rft.issue=4&rft.spage=905&rft.epage=912&rft.pages=905-912&rft.issn=0009-9163&rft.eissn=1399-0004&rft_id=info:doi/10.1111/cge.13184&rft_dat=%3Cproquest_cross%3E2013610730%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2013610730&rft_id=info:pmid/29193034&rfr_iscdi=true |